GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (FRA:1I4) » Definitions » EV-to-FCF

HeraMED (FRA:1I4) EV-to-FCF : -2.43 (As of Mar. 26, 2025)


View and export this data going back to 2019. Start your Free Trial

What is HeraMED EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, HeraMED's Enterprise Value is €7.32 Mil. HeraMED's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-3.01 Mil. Therefore, HeraMED's EV-to-FCF for today is -2.43.

The historical rank and industry rank for HeraMED's EV-to-FCF or its related term are showing as below:

FRA:1I4' s EV-to-FCF Range Over the Past 10 Years
Min: -10.83   Med: -2.87   Max: -0.15
Current: -2.56

During the past 7 years, the highest EV-to-FCF of HeraMED was -0.15. The lowest was -10.83. And the median was -2.87.

FRA:1I4's EV-to-FCF is ranked worse than
100% of 380 companies
in the Medical Devices & Instruments industry
Industry Median: 27.19 vs FRA:1I4: -2.56

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-26), HeraMED's stock price is €0.009. HeraMED's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.008. Therefore, HeraMED's PE Ratio (TTM) for today is At Loss.


HeraMED EV-to-FCF Historical Data

The historical data trend for HeraMED's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED EV-to-FCF Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial -3.86 -9.83 -5.60 -1.25 -3.16

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.60 - -1.25 - -3.16

Competitive Comparison of HeraMED's EV-to-FCF

For the Medical Devices subindustry, HeraMED's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeraMED's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where HeraMED's EV-to-FCF falls into.


';

HeraMED EV-to-FCF Calculation

HeraMED's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7.315/-3.014
=-2.43

HeraMED's current Enterprise Value is €7.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HeraMED's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-3.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeraMED  (FRA:1I4) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

HeraMED's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.009/-0.008
=At Loss

HeraMED's share price for today is €0.009.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HeraMED's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


HeraMED EV-to-FCF Related Terms

Thank you for viewing the detailed overview of HeraMED's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


HeraMED Business Description

Traded in Other Exchanges
Address
201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines